Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • S&P 500

    5,253.63
    +5.14 (+0.10%)
     
  • Dow

    39,742.01
    -18.07 (-0.05%)
     
  • Nasdaq

    16,401.93
    +2.41 (+0.01%)
     
  • Bitcoin USD

    71,493.73
    +1,594.96 (+2.28%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,971.33
    +39.35 (+0.50%)
     
  • Gold

    2,234.30
    +21.60 (+0.98%)
     
  • Crude Oil

    82.62
    +1.27 (+1.56%)
     
  • 10-Yr Bond

    4.1980
    +0.0020 (+0.05%)
     
  • Nikkei

    40,168.07
    -594.66 (-1.46%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE Bursa Malaysia

    1,530.60
    -7.82 (-0.51%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Why This FDA Approval Is a Game Changer for Eli Lilly

Why This FDA Approval Is a Game Changer for Eli Lilly

Eli Lilly (NYSE: LLY) is a top healthcare company that continually finds new ways to grow and create value for its investors. One of the company's recent diabetes treatments has obtained approval from the U.S. Food and Drug Administration (FDA). On May 13, Eli Lilly announced that the FDA had approved Mounjaro (tirzepatide) to treat people with type 2 diabetes.